Turn Therapeutics (NASDAQ: TTRX) gets new cash from existing backers
Rhea-AI Filing Summary
Turn Therapeutics Inc. entered into securities purchase agreements with certain accredited investors, primarily existing series and seed investors, to complete a private equity financing. The company agreed to issue and sell 135,000 shares of common stock at a purchase price of $10.00 per share, resulting in aggregate gross proceeds of $1.35 million.
The transaction was structured as a private placement relying on the registration exemptions under Section 4(a)(2) of the Securities Act of 1933 and Regulation D for transactions not involving a public offering. Turn Therapeutics also granted the investors registration rights for these shares, enabling potential future resale under a registration statement.
Positive
- Turn Therapeutics raised $1.35 million in gross proceeds through a private placement of common stock, providing additional capital from existing accredited investors.
Negative
- None.
Filing Explained
The filing sets out a $1.35 million private placement whose 135,000 shares would reduce existing holders’ percentage ownership if issued.
The filing both reports agreements to issue and sell 135,000 common shares for
If issued, the additional shares would increase the total share count and reduce existing holders’ percentage ownership, absent offsetting changes.
The private-placement structure concerns the offering route, while the granted registration rights concern potential later resale registration; neither establishes that the financing proceeds have been received.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Shares Issued: 135,000 shares
Purchase Price per Share: $10.00 per share
Aggregate Gross Proceeds: $1.35 million
+1 more
4 metrics
Shares Issued
135,000 shares
Common stock issued in the August 14, 2026 private placement
Purchase Price per Share
$10.00 per share
Price paid by accredited investors for each share of common stock
Aggregate Gross Proceeds
$1.35 million
Total gross proceeds from the private placement of 135,000 shares
Par Value
$0.0001 per share
Par value of Turn Therapeutics common stock
Key Terms
securities purchase agreements, accredited investors, private placement, Regulation D, +2 more
6 terms
securities purchase agreements financial
"entered into securities purchase agreements with certain accredited investors"
A securities purchase agreement is a legal contract that spells out the terms when a company sells stocks, bonds, or other investment instruments to buyers. It lays out price, how many securities change hands, any promises or protections for each side, and when the sale is completed—like a detailed sales contract for investments. Investors care because it determines ownership stakes, potential dilution, rights attached to the securities, and conditions that affect the company’s future value.
accredited investors financial
"securities purchase agreements with certain accredited investors, consisting of existing series"
Accredited investors are individuals or entities considered to have enough financial knowledge and resources to understand and handle more complex and risky investments. They are often allowed to participate in private investment opportunities that are not available to the general public, similar to how experienced players might access exclusive clubs or events. This status helps ensure that investors can manage potential risks and rewards appropriately.
private placement financial
"The Shares were sold in a private placement in reliance on the exemption"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
Regulation D financial
"in reliance on the exemption from registration provided by Section 4(a)(2) and Regulation D"
Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.
Section 4(a)(2) financial
"exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933"
Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.
registration rights financial
"The Company granted the Investors certain registration rights with respect to the Shares"
Registration rights are contractual promises that let investors require a company to file paperwork with securities regulators so those investors can sell their shares to the public. They matter because they create a path to liquidity and an exit plan—without them, investors may be stuck holding shares for a long time. Think of them like a reserved ticket that guarantees access to a public marketplace when the holder is ready to sell.
FAQ
What financing transaction did TTRX announce on August 14, 2026?
Turn Therapeutics Inc. announced a private placement with accredited investors, agreeing to sell 135,000 shares of common stock at $10.00 per share, for $1.35 million in aggregate gross proceeds.
Who participated in Turn Therapeutics (TTRX) August 2026 private placement?
The private placement involved accredited investors, consisting of the company’s existing series and seed investors. These investors entered into securities purchase agreements to buy common stock directly from Turn Therapeutics.
What securities law exemptions did TTRX rely on for this offering?
Turn Therapeutics relied on Section 4(a)(2) of the Securities Act of 1933 and Regulation D exemptions. These provisions allow private placements to accredited investors as transactions not involving a public offering.
Did investors in TTRX’s August 2026 financing receive registration rights?
Yes. Turn Therapeutics granted the investors registration rights for the newly issued shares. These rights allow investors to request or participate in a future registration statement to facilitate potential resale of their shares.
Is the August 14, 2026 TTRX financing information considered filed under the Exchange Act?
The company stated that the information under Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference into other filings, except where specifically referenced.
AI-generated analysis. How Rhea-AI works. Not financial advice.
